Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

NCT00730405 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.

NCT NCT00730405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00730405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
Lead sponsor
Stiefel, a GSK Company
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2008
Completion date
February 19, 2010
Enrollment
582 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

onychomycosis